GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes
- 16 August 2011
- journal article
- research article
- Published by Hindawi Limited in Pediatric Diabetes
- Vol. 13 (3) , 244-250
Abstract
Skoglund C, Chéramy M, Casas R, Ludvigsson J, Hampe CS. GAD autoantibody epitope pattern after GAD‐alum treatment in children and adolescents with type 1 diabetes. Aims: We have previously shown that two injections of glutamic acid decarboxylase formulated in alum (GAD‐alum) preserved residual insulin secretion in children and adolescents with recent onset type 1 diabetes (T1D), and was accompanied by increased GAD autoantibody (GADA) titers. The aim of this study was to investigate whether GAD‐alum treatment affected the GADA epitope pattern. Methods: Serum samples from patients treated with GAD‐alum (n = 33) or placebo (n = 27), at baseline, 1, 3, 9, and 15 months after the initial injection, were tested for their binding capacity to specific GADA epitopes in an epitope‐specific radioligand binding assay with six recombinant Fab (rFab) (b96.11, DPA, DPD, MICA3, b78, and N‐GAD65 mAb). Results: No significant differences in variability of binding to any of the tested rFab were observed from baseline to 15 months. There was a sustained low binding of GADA to the b78‐ and N‐GAD65 mAb‐defined epitopes, often recognized by GADA in patients with stiff person syndrome (SPS) and seldom in T1D patients. However, binding of GADA to the T1D‐associated b96.11‐defined epitope increased between baseline and 3 months in GAD‐alum (−8.1%, min −72.4%, max 39.6%) compared to placebo patients (1.5%, min −28.3%, max 28.6%) (p = 0.02). Subsequently, the b96.11‐defined epitope recognition returned to levels similar to that observed at baseline. Conclusions: GAD‐alum injections did not affect binding of GADA to SPS‐related epitopes, further supporting the safety of the treatment. There were no changes in GADA epitope specificity to the T1D‐related epitopes, except for a temporarily increased binding to one of the tested epitopes.Keywords
This publication has 41 references indexed in Scilit:
- Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapyJournal of Autoimmunity, 2010
- GAD Treatment and Insulin Secretion in Recent-Onset Type 1 DiabetesNew England Journal of Medicine, 2008
- Effects of Oral Insulin in Relatives of Patients With Type 1 DiabetesDiabetes Care, 2005
- Immune modulation for prevention of type 1 diabetes mellitusTrends in Biotechnology, 2005
- Does GAD Have a Unique Role in Triggering IDDM?Journal of Autoimmunity, 2000
- Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes.Journal of Experimental Medicine, 1996
- Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic miceNature, 1993
- Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetesNature, 1993
- Insulitis in type 1 (insulin‐dependent) diabetes mellitus in man—macrophages, lymphocytes, and interferon‐γ containing cellsThe Journal of Pathology, 1991
- Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylaseNature, 1990